Quan Capital
China's Alebund Pharma gets $145m in debt, equity funding
Alebund Pharmaceuticals has raised close to CNY 200m (USD 29m) in a pre-Series C funding round. Investors include state-owned Yangzhou Guojin Investment and Yangzhou Longchuan Holdings.
Cenova leads $40m Series B for China's Eluminex
China-based healthcare investor Cenova Capital has led a USD 40m Series B round for Eluminex Biosciences, which is developing drugs and regenerative tissue used to treat eye disease and other vision-threatening medical conditions.
Qiming, Quan lead $120m Series B for China's OriCell
Qiming Venture Partners and Quan Capital have led a USD 120m Series B round for OriCell Therapeutics, a China-based drug developer that is working on CAR-T cell therapies that target cancer.
China RNA vaccine developer raises $42m
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
China biotech: Going global
A gradual shift in focus from sourcing assets from overseas for application in China to bringing China-made treatments to the world is challenging the notion of what constitutes a local biotech start-up
Chinese vision therapy start-up Elumninex raises $50m
Chinese eye disease specialist Elumninex Biosciences has raised a $50 million Series A round led by GL Ventures, Lilly Asia Ventures (LAV), and Quan Capital.
China's Quan Capital raises $275m for second healthcare fund
Quan Capital, a healthcare-focused venture capital firm established by the founder of US-listed Chinese drug developer Zai Lab, has closed its second fund with $275 million in commitments.